never say "never", it gives you away.
difficult to counter your assessment of compassionate use. Unfortunately there are a lot of extenuating circumstances involved.
Do not rely on the oncologist knowing about NeuVax. I questions my wife's oncologist 3 years ago about the clinical trials in progress, he did a quick search in the room and came up with a quick vacuum cleaner response......not very thorough....he wrote it off but did comment that cancer vaccines may play an important roll in treatment eventually.
How about $2 billion with royalties for all of Europe and Africa, 2 Billion for rights and royalties for Asia and Australia and Keep U S A for Galena.....I could live with that.
I don't believe Schwartz would even consider anything close to $8 given his remark about the multi billion market in the U. S.
Feb. 10 issue, Anybody read it ?
Packed full of info, somebody with a better working knowledge of this information would be better suited to discuss this info. If not will try to go over highlights.
One of the paragraphs goes over the prolonged plasma SN38 Exposure Compared with Irinotecan,
"In patients, etirinotecn pegol has been shown to lead to greatly prolonged plasma SN38 exposure compared with what is possible with irinotecan. Hope somebody has access too this article and discuss the info.
Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. Think DR. Reddy and the upcoming Neu Vax clinical then add Herceptin =Genetech
Another reason Genetech might couple with Galena.....Getting better everyday.